Specialty Pharmacy

Partnership will commemorate the event with a webinar and presentation of Woman Pharmacist of the Year award on Oct. 12.

Like diabetes, Inflammatory bowel disease may also be linked to a high-fructose diet.

IMGN632 granted breakthrough designation for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.

Integrating specialty pharmacy staff into oncology, neurology, rheumatology, and other specialty clinics within their health systems is a growing trend with a range of beneficial outcomes.

Nivolumab plus ipilimumab is the first immunotherapy approved for previously untreated unresectable malignant pleural mesothelioma.

During American Pharmacists Month, the National Association of Chain Drug Stores is honoring the role of pharmacists as the most accessible point of health care for patients, particularly among those in the greatest need.

Pharmacy Times will be celebrating pharmacists throughout the month of October to recognize their contributions to the health care field, especially in the ongoing coronavirus disease 2019 pandemic.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

The FDA has approved golimumab for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.

Intravenous Immunoglobulin helps to improve hypoxia, which can reduce the need for mechanical ventilation.

The results of an additional secondary endpoint from the phase 3 HERO study evaluating oral relugolix in men with advanced prostate cancer showed that relugolix had a similar rate of castration resistance-free survival compared to intravenous leuprolide acetate in men with metastatic disease through 48 weeks.

The FDA has approved mepolizumab for the treatment of hypereosinophilic syndrome.

Pregnancy may help put off the onset of multiple sclerosis symptoms by more than 3 years.

Using a 3D model, investigators found a soy-based compound was effective in treating bone cancer.

At ESMO 2020, researchers discussed some long-awaited data regarding postoperative radiotherapy used in patients with non-small cell lung cancer following complete resection and after (neo) adjuvant chemotherapy.

New drug application been submitted for TLX591-CDx (illumet), a radiopharmaceutical product that targets prostate-specific membrane antigen for the imaging of prostate cancer.

Among patients with cervical cancer, there was no significant difference found between the risk of recurrence, local recurrence, or death among individuals who either completed or abandoned a radical uterine procedure following the intraoperative detection of a positive pelvic lymph node.

Top news of the week from Pharmacy Times®.

The FDA has granted fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression.

An overview of the most common human resources problems that pharmacies face and the proactive steps that pharmacies can take to avoid these problems.

Study shows that upon hospital admission for cancer, many patients already have a high prevalence of malnutrition per Global Leadership Initiative on Malnutrition criteria.

The results from a cohort of patients with rare sarcomas in the phase 2 study, presented by professor Jean-Yves Blay, MD, investigated the efficacy and safety of single agent pembrolizumab in rare cancers.

A new study showed that nivolumab was effective in patients with pathogenic exonuclease domain POLE mutated mismatch repair.

The effects of pralsentinib were especially pronounced in treatment-naïve patients with medullary thyroid cancer.

The predictive value provided by T effector and angiogenesis signatures were found to be augmented by Kidney Immune Classification of tumor microenvironments.

Although immune checkpoint inhibitors are not yet approved for first-line therapy in these populations, the new research could lead to a new standard of care.

Adding atezolizumab (Tecentriq) to bevacizumab (Avastin) and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

More than half of high-risk patients with resected, stage III BRAF V600-mutated melanoma who were treated with dabrafenib and trametinib were alive and relapse-free at 5 years.

The COVID-19 pandemic will be felt in the oncology space long after the pandemic is over, study shows.

The CheckMate 9ER trial took 2 drugs used as monotherapies in the second line of therapy, nivolumab and cabozantinib, and combined them for use as a first-line treatment against standard of care, sunitinib.